Table 3.

Response rate and clinical benefit by immune therapy type

NRAS mutantBRAF mutantWT
n = 11n = 14n = 23
Anti–PD-1/PD-L1
 Objective response7 (64%)3 (21%)8 (35%)
 Clinical benefit8 (73%)3 (21%)10 (43%)
Ipilimumabn = 43n = 31n = 95
 Objective response8 (19%)4 (13%)10 (11%)
 Clinical benefit18 (42%)5 (16%)19 (20%)
IL2n = 15n = 29n = 19
 Objective response5 (33%)6 (21%)5 (26%)
 Clinical benefit5 (33%)11 (34%)7 (37%)